Latest Peplin news



Form 10-Q quarterly report read more

Peplin Results for the Quarter Ended 31 December 2008 read more


Positive results for Peplin's Phase IIb AK Trial read more


Peplin completes enrolment for its first phase III AK clinical trial read more


Form 10-Q - Quarterly Report read more

Registration statement including financial report read more

Welcome to Peplin

We are a Phase III specialty pharmaceutical company focused on advancing and commercializing innovative medical dermatology products. We are currently developing PEP005 (ingenol mebutate), or PEP005, which is the first in a new class of compounds and which is derived from Euphorbia peplus, or E. peplus, a rapidly growing, readily-available plant, commonly referred to as petty spurge or radium weed. The sap of E. peplus has a long history of traditional use for a variety of conditions, including the topical self-treatment of various skin disorders, such as skin cancer and pre-cancerous skin lesions. Peplin has extensive international patent coverage over its technologies.

Company Highlights

$24m financing and Neosil acquisition complete

Phase IIb Positive Results

Peplin announced positive results for PEP005 (ingenol mebutate) Gel in its Phase IIb actinic (solar) keratosis (AK) dose ranging clinical trial (PEP005-015) for the treatment of AK lesions on head locations. The trial met the primary efficacy endpoint with statistically significant complete clearance rate of AK lesions vs. vehicle. In addition, there was a reduction in overall lesion count in all active treatment groups. The side effects were well-tolerated local skin responses which dissolved rapidly at all concentrations and durations.

region-i trial underway

REGION-I Trial Enrolment Complete

Peplin has completed enrolment of its US and Australian 250 patient Phase III clinical trial to confirm the efficacy and safety of PEP005 ingenol mebutate) Gel for the treatment of actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, when applied to non-head locations, which include the trunk and extremities.

$24m financing and Neosil acquisition complete

$24m financing and Neosil acquisition complete

Peplin has closed its acquisition of Neosil, providing ~$6m in cash plus early stage dermatology assets, and raised $24m in financing lead by new investor GBS and including existing investors MPM, NEA, and Orbis. This provides a June 30, 2008 pro-forma balance = $56m, sufficient amount to fund Phase III development.

Sign up to receive email alerts regarding Peplin news and financials here

Contact us

Medical information

Telephone: +1-800-881-5754

Clinical trial information

Please refer to: for trial information

Corporate information



6475 Christie Avenue
Suite 300
Emeryville, California 94608

Telephone: +1-510 653 9700
Facsimile: +1-510 653 9704


Level 2, Brisbane Portal
1 Breakfast Creek Road
Brisbane, Queensland 4006
Telephone: +61-7-3250 1200
Facsimile: +61-7-3250 1299